This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

V. LOGAN LOVE, M.D.

Arch Intern Med. 1961;108(6):833-836.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The role of thyroxine in the control of serum cholesterol has long been recognized clinically. In hypothyroidism hypercholesteremia assumes some diagnostic importance; whereas, a tendency to hypocholesteremia is often recorded in hyperthyroidism. The administration of desiccated thyroid and thyroid extracts will reduce the serum cholesterol and phospholipid.¹

At the present time a rather voluminous literature points to the probability that elevated lipids constitute one of the factors involved in atherogenesis. Therefore, if thyroxine could be altered so as to maintain its cholesterol-lowering effect without altering general body metabolism a useful research and possible therapeutic tool would be available. It is the purpose of this paper to present a clinical experience with one of these thyroxine analogues.

Tetraiodothyroformic acid (TFA-4) is formulated by substituting a carboxyl group for the alanine side-chain of thyroxine (Fig. 1). Duncan and Best^2-4 studied this compound in rats and found that, when compared to . . . [Full Text PDF of this Article]

Author Affiliations
MARION, IND.

From the Department of Medicine, Davis Clinic.; Assistant in Medicine, Indiana University School of Medicine, Indianapolis.

Footnotes
Submitted for publication Dec. 20, 1960.

This study was supported in part by grants from Eli Lilly & Co., Indianapolis, to the Davis Medical Foundation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?